A Study of Fruquintinib in Combination With Tislelizumab in Advanced Triple Negative Breast Cancer
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multi-center, non-randomized, Phase 1b/2 study to assess the safety
and efficacy of fruquintinib in combination with tislelizumab in patients with advanced,
refractory TNBC. This study will be conducted in 2 parts; a safety lead-in phase (Part 1) and
a dose expansion phase (Part 2). The safety lead-in phase will determine the RP2D. The RP2D
will be administered to 2 cohorts of patients in the expansion phase.
- Cohort A: TNBC (IO-treated)
- Cohort B: TNBC (IO-Naïve)